Diagnostic Publications
ZeptoMetrix provides scientific publications that reference and/or cite our products. Search diagnostic publications below.
A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24/a>
September 2024: The introduction of combined antiretroviral therapy (cART) has greatly improved the quality of life of human immunodeficiency virus type 1 (HIV-1)-infected individuals. Nonetheless, the ever-present desire to seek out a full remedy for HIV-1 infections makes the discovery of novel antiviral medication compelling. Owing to this, a new late-stage inhibitor, Lenacapavir/Sunlenca, an HIV multi-phase suppressor, was clinically authorized in 2022. Besides unveiling cutting-edge antivirals inhibiting late-stage proteins or processes, newer therapeutics targeting host restriction factors hold promise for the curative care of HIV-1 infections.
Performance Characteristics of a Real-Time PCR Assay for Direct Detection of Streptococcus pneumoniae in Clinical Specimens
July 2024: Community-acquired pneumonia and complications, such as bacteremia and meningitis due to Streptococcus pneumoniae infection, still occur in at-risk populations, despite the availability of effective vaccines. Laboratory confirmation of S. pneumoniae remains challenging despite advances in blood culture techniques and the availability of nucleic acid–amplification tests. The goal of this study was to determine the performance characteristics of a molecular assay designed as a diagnostic test using primary clinical specimens for invasive pneumococcal disease.
Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; Cepheid Xpert® Xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARD™ M10 Flu/RSV/SARS-CoV-2
June 2024: Rapid and accurate detection of viral respiratory infections is important for infection control measures. This study compares the analytical and clinical performance of the Xpert® Xpress CoV-2/Flu/RSV plus test (“Xpert”, Cepheid) and the STANDARD™ M10 Flu/RSV/SARS-CoV-2 test (“M10”, SD Biosensor). Both tests are quadruplex RT-PCR assays for rapid diagnosis of SARS-CoV-2, influenza A/B and RSV.
Evaluation of HSV PCR testing on CSF across 3 platforms
February 2024: To determine the limit of detection (LOD) of the BioFireME compared to another commercial assay (Seegene Allplex Meningitis-V1) and our validated in-house HSV PCR, we used a third-party (ZeptoMetrix NATtrol™) positive control as sample material. Samples were tested in serial tenfold dilutions to 10-7.